Expect balanced development of medical care through sharing and integration of medical data
At a time when the rate of population aging is accelerating, research on diseases caused by aging of the body is more urgent than anything else. We met and talked with Professor Yoo Jun-il, who is the CTO of 'Doctor Log', a data collection and utilization system for the prevention and treatment of geriatric fractures that cause gait disorders, and is contributing to the growth of domestic bio ventures by leading the open laboratory at Gyeongsang National University Hospital.
Q. Medius Queen: Hello. Gyeongsang National University Hospital (hereafter referred to as Gyeongsang National University Hospital) orthopedic specialist in hip joint disease and fractures for the elderly, working as CTO of Dr. Log and doing various jobs as a digital healthcare leader. Please introduce yourself.
A. Professor Yoo Jun-il of the Department of Orthopedic Surgery at Gyeongsang National University Hospital (hereafter Yoo Jun-il): Currently, as an orthopedic surgeon at Gyeongsang National University Hospital, he is active in surgery, treatment, and research as a specialist in hip joint disease and elderly fractures. He is usually interested in medical IT or big data, so he established Divo Co., Ltd. as a joint venture with Professor Kang Yang-je of the Department of Bioinformatics at Chungbuk National University three years ago and developed Doctor Log. He is currently responsible for Dr. Log's life big data business and research.
Q. MEDIEUS QUEEN: You serve as the deputy director of the open laboratory specializing in infectious diseases at Gyeongsang National University Hospital, helping bio companies grow and expand their medical infrastructure. Please explain in detail what kind of work the open laboratory does.
A. Yoo Junil: There are many bio companies in Korea. However, the threshold of the hospital is very high, and the actual needs are created by the medical staff inside the hospital. That is why the meeting place between hospital medical staff and doctors and bio companies is very important. However, in reality, there are many cases where people meet through intermittent events or assignments, and even that is made up of a few related connections. In particular, it is more difficult to have such a point of contact in non-metropolitan areas. Therefore, the open laboratory at Gyeongsang National University Hospital is doing things that support local companies in discovering companies, creating demand, and joint research and development with medical staff. A bio company moves into the hospital and develops technology and products with medical staff for as little as 1 year and as long as 3 years. Through this, technology development, which can take several years, is reduced to one year at the shortest, and this process naturally leads to clinical trials. In addition, user suitability is very important for medical devices and biotechnology, and this also has many advantages that can be solved immediately. In particular, our open laboratory focuses on non-face-to-face technologies as an item specialized for infectious diseases, and is developing digital treatments, distributed clinical trials, and IoT devices.
Q. MEDIEUS QUEEN: Research is being conducted to accumulate actual use data for sarcopenia and artificial intelligence medical devices. I heard that you were selected. Please explain the contents of your research.
A. Yoo Jun-il: We are promoting the ‘Real World Data (RWD)-based Clinical Evidence Creation Support Project’ supported by the Ministry of Health and Welfare and the Korea Health Industry Development Institute. The goal is to overcome sarcopenia, a causative disease of hip fracture, and to accumulate actual use data of artificial intelligence medical devices through RSE establishment research on hip fractures in the elderly. The research project will be conducted for about 3 years until December 2024 with Gyeongsang National University Hospital in charge, and Ajou University Hospital, Daejeon University Hospital, Seoul Nowon Eulji University Hospital, etc. will participate, and based on actual use data collected, the effectiveness of digital therapeutics and artificial intelligence medical devices and the basis for safety verification. The ultimate goal of these real-use data is to produce clinical evidence for the prevention, treatment, and diagnosis of hip fractures in the elderly, as well as data that can be used for future digital treatment and artificial intelligence medical technology.
Q. MEDIEUS QUEEN: If the Dr.Log business mentioned above is activated, it seems to be of great help not only to doctors but also to patients. Specifically, how can patients receive treatment?
A. Yoo Jun-il : In fact, following Dr. Log for doctors, the ‘Doctor DM (Direct Message)’ app for patients has been released. Clinical trials are currently underway through this app. First, patients can ask their doctor questions through Dr. DM, and there are still legal problems with non-face-to-face treatment in Korea, but treatment time is limited to patients who spend a day or two for simple treatment from Jinju to Seoul. could be drastically reduced. In addition, we are currently developing and testing a service in which digital treatment prescribed through Dr.Log is monitored through Dr. DM. This technology, as a key technology for the clinical trial platform for digital therapeutics, will be used to build RWD that secures the effectiveness and safety of various digital treatment devices and IoT devices and to establish a seamless remote digital treatment foundation. In addition, it cannot be solved by increasing the number of doctors to smoothly expand medical services in the mountainous and island regions of Gyeongsangnam-do. The technology will also be used to fill the medical gap in areas that are hard to reach for doctors.
Q. MEDIEUS QUEEN: You said that you have a role to play as a professor at a national university base hospital, and you are doing a lot of activities. It seems that there are many difficulties in the medical system environment centered on the metropolitan area. Please tell us about the balanced development of medical care and the role of national university base hospitals.
A. Yoo Jun-il: As a doctor who has lived in a medical system centered on the metropolitan area, I had many difficulties while living in the provinces for 6-7 years. First of all, since many patients go to the metropolitan area to receive treatment, there are many gaps in important medical information. Therefore, for this medical data integration, medical data brokerage services such as Dr.Log, including My Data business, must be more active. For reasons of medical data security, the sharing of medical data, which is really necessary, is not being done. More innovative and enterprising opening is needed in a way that compensates for problems by expanding empirical evidence from the safe part rather than regulating. Here, the base national hospital should not simply focus on public medical care, but should also strive to develop technology for sharing and utilizing such medical data. To this end, local government agencies need to discover and develop various local companies rather than collaborating with companies focused on the metropolitan area. Efforts to recruit and develop local talents should be accompanied by the relocation of affiliated research institutes and new business divisions of companies in the metropolitan area.
Q. MEDIEUS QUEEN: Lastly, with the recent COVID-19 outbreak, interest in digital healthcare is increasing and many services are emerging. Please give your opinion on the development direction of the digital healthcare industry in your opinion. And if you have any personal plans or goals, please let me know.
A. Yoo Jun-il: The development of disease prevention and prediction services centered on personal medical data and consequently, additional healthcare businesses will increase. I also experienced the convenience and usefulness of non-face-to-face and remote medical care in the wake of the COVID-19 pandemic. I believe that these fields will lead to the development of numerous medical devices and non-face-to-face clinical trials of new drugs developed in the future. New drug-oriented domestic biohealth is not leading the global healthcare sector. However, IT-centered digital treatment technology and IoT monitoring technology have developed further while experiencing Corona, and Korea will lead this field in the future in the global healthcare market. In this field, our goal is to become the global No. 1 company in new areas such as digital therapeutics clinical trial platform, distributed clinical trial, and artificial intelligence motion analysis.
A. Professor Yoo Jun-il of the Department of Orthopedic Surgery at Gyeongsang National University Hospital (hereafter Yoo Jun-il): Currently, as an orthopedic surgeon at Gyeongsang National University Hospital, he is active in surgery, treatment, and research as a specialist in hip joint disease and elderly fractures. He is usually interested in medical IT or big data, so he established Divo Co., Ltd. as a joint venture with Professor Kang Yang-je of the Department of Bioinformatics at Chungbuk National University three years ago and developed Doctor Log. He is currently responsible for Dr. Log's life big data business and research.
Q. MEDIEUS QUEEN: You serve as the deputy director of the open laboratory specializing in infectious diseases at Gyeongsang National University Hospital, helping bio companies grow and expand their medical infrastructure. Please explain in detail what kind of work the open laboratory does.
A. Yoo Junil: There are many bio companies in Korea. However, the threshold of the hospital is very high, and the actual needs are created by the medical staff inside the hospital. That is why the meeting place between hospital medical staff and doctors and bio companies is very important. However, in reality, there are many cases where people meet through intermittent events or assignments, and even that is made up of a few related connections. In particular, it is more difficult to have such a point of contact in non-metropolitan areas. Therefore, the open laboratory at Gyeongsang National University Hospital is doing things that support local companies in discovering companies, creating demand, and joint research and development with medical staff. A bio company moves into the hospital and develops technology and products with medical staff for as little as 1 year and as long as 3 years. Through this, technology development, which can take several years, is reduced to one year at the shortest, and this process naturally leads to clinical trials. In addition, user suitability is very important for medical devices and biotechnology, and this also has many advantages that can be solved immediately. In particular, our open laboratory focuses on non-face-to-face technologies as an item specialized for infectious diseases, and is developing digital treatments, distributed clinical trials, and IoT devices.
Q. MEDIEUS QUEEN: Research is being conducted to accumulate actual use data for sarcopenia and artificial intelligence medical devices. I heard that you were selected. Please explain the contents of your research.
A. Yoo Jun-il: We are promoting the ‘Real World Data (RWD)-based Clinical Evidence Creation Support Project’ supported by the Ministry of Health and Welfare and the Korea Health Industry Development Institute. The goal is to overcome sarcopenia, a causative disease of hip fracture, and to accumulate actual use data of artificial intelligence medical devices through RSE establishment research on hip fractures in the elderly. The research project will be conducted for about 3 years until December 2024 with Gyeongsang National University Hospital in charge, and Ajou University Hospital, Daejeon University Hospital, Seoul Nowon Eulji University Hospital, etc. will participate, and based on actual use data collected, the effectiveness of digital therapeutics and artificial intelligence medical devices and the basis for safety verification. The ultimate goal of these real-use data is to produce clinical evidence for the prevention, treatment, and diagnosis of hip fractures in the elderly, as well as data that can be used for future digital treatment and artificial intelligence medical technology.
Q. MEDIEUS QUEEN: If the Dr.Log business mentioned above is activated, it seems to be of great help not only to doctors but also to patients. Specifically, how can patients receive treatment?
A. Yoo Jun-il : In fact, following Dr. Log for doctors, the ‘Doctor DM (Direct Message)’ app for patients has been released. Clinical trials are currently underway through this app. First, patients can ask their doctor questions through Dr. DM, and there are still legal problems with non-face-to-face treatment in Korea, but treatment time is limited to patients who spend a day or two for simple treatment from Jinju to Seoul. could be drastically reduced. In addition, we are currently developing and testing a service in which digital treatment prescribed through Dr.Log is monitored through Dr. DM. This technology, as a key technology for the clinical trial platform for digital therapeutics, will be used to build RWD that secures the effectiveness and safety of various digital treatment devices and IoT devices and to establish a seamless remote digital treatment foundation. In addition, it cannot be solved by increasing the number of doctors to smoothly expand medical services in the mountainous and island regions of Gyeongsangnam-do. The technology will also be used to fill the medical gap in areas that are hard to reach for doctors.
Q. MEDIEUS QUEEN: You said that you have a role to play as a professor at a national university base hospital, and you are doing a lot of activities. It seems that there are many difficulties in the medical system environment centered on the metropolitan area. Please tell us about the balanced development of medical care and the role of national university base hospitals.
A. Yoo Jun-il: As a doctor who has lived in a medical system centered on the metropolitan area, I had many difficulties while living in the provinces for 6-7 years. First of all, since many patients go to the metropolitan area to receive treatment, there are many gaps in important medical information. Therefore, for this medical data integration, medical data brokerage services such as Dr.Log, including My Data business, must be more active. For reasons of medical data security, the sharing of medical data, which is really necessary, is not being done. More innovative and enterprising opening is needed in a way that compensates for problems by expanding empirical evidence from the safe part rather than regulating. Here, the base national hospital should not simply focus on public medical care, but should also strive to develop technology for sharing and utilizing such medical data. To this end, local government agencies need to discover and develop various local companies rather than collaborating with companies focused on the metropolitan area. Efforts to recruit and develop local talents should be accompanied by the relocation of affiliated research institutes and new business divisions of companies in the metropolitan area.
Q. MEDIEUS QUEEN: Lastly, with the recent COVID-19 outbreak, interest in digital healthcare is increasing and many services are emerging. Please give your opinion on the development direction of the digital healthcare industry in your opinion. And if you have any personal plans or goals, please let me know.
A. Yoo Jun-il: The development of disease prevention and prediction services centered on personal medical data and consequently, additional healthcare businesses will increase. I also experienced the convenience and usefulness of non-face-to-face and remote medical care in the wake of the COVID-19 pandemic. I believe that these fields will lead to the development of numerous medical devices and non-face-to-face clinical trials of new drugs developed in the future. New drug-oriented domestic biohealth is not leading the global healthcare sector. However, IT-centered digital treatment technology and IoT monitoring technology have developed further while experiencing Corona, and Korea will lead this field in the future in the global healthcare market. In this field, our goal is to become the global No. 1 company in new areas such as digital therapeutics clinical trial platform, distributed clinical trial, and artificial intelligence motion analysis.
#Medieus #Interview #Gyeongsang National University Hospital #Orthopedics #Elderly Fractures #Health Care #Doctor Log #Medical Data Sharing #Big Data #Digital Treatment #Distributed Clinical Trial #Artificial Intelligence Motion Analysis
 |
CEO 박보현
메디컬 커머셜 플랫폼, 메디우스 (주)비앤에이치코리아 대표이사
국내최고 디지털마케팅 전문가
[월간 CEO&] 의료전문 컬럼니스트
인터뷰 문의:sales@bnhkorea.co.kr
|